Ashwin Kishtagari, MBBS, MSCI
  • Slides
  • Talks
  • R notes
  • Notebooks
  • Topics
    • Myeloproliferative neoplasms
    • Acute leukemia
    • Bone marrow failure
    • Clonal hematopoiesis
    • Biostatistics
  • Resources
  • About
Categories

Slide decks

Every deck in the library, generated automatically from the repository.

This page rebuilds itself from the .qmd files in topics/*/slides/. Add a deck, render, push — it appears here. Nothing to maintain by hand.

Use the search box to filter by any word in a title or description, or click a topic tag to narrow the list.

Updated Title Description Topic
Aug 18, 2026 Acute Promyelocytic Leukemia for Fellows    
Aug 18, 2026 Closing the Disease Modification Gap Emerging Therapies in Myelofibrosis Beyond JAK Inhibition  
Aug 18, 2026 Data Visualization Topic 03 · ggplot2 & Grammar of Graphics  
Aug 18, 2026 Data Wrangling Topic 02 · Tidy Data  
Aug 18, 2026 Essential Thrombocythemia Topic 04 · Myeloproliferative Neoplasms  
Aug 18, 2026 Introduction to Statistics Topic 01 · Foundations  
Aug 18, 2026 Risk Stratification in Polycythemia Vera Topic 05 · Myeloproliferative Neoplasms  
Aug 18, 2026 Ruxolitinib in Myelofibrosis Topic 07 · Myeloproliferative Neoplasms  
Aug 18, 2026 Ruxolitinib in Polycythemia Vera Topic 05 · Myeloproliferative Neoplasms  
Aug 18, 2026 Ruxolitinib in Polycythemia Vera Topic 05 · Myeloproliferative Neoplasms  
Aug 18, 2026 TEMPLATE — Replace Me Topic subtitle  
Aug 18, 2026 TEMPLATE — Replace Me Topic subtitle  
Aug 18, 2026 TEMPLATE — Replace Me Topic subtitle  
Aug 18, 2026 TEMPLATE — Replace Me Topic subtitle  
Aug 18, 2026 TEMPLATE — Replace Me Topic subtitle  
Aug 18, 2026 Targeting Mutant Calreticulin in Essential Thrombocythemia INCA033989 · EHA 2026 (PS1983, Mascarenhas et al.)  
Aug 18, 2026 Targeting Mutant Calreticulin in Myelofibrosis INCA033989 · EHA 2026 (Harrison oral; Nangalia PF884)  
Aug 16, 2026 Clonal Hematopoiesis in Sickle Cell Disease Clinical implications in the era of curative therapy  
Aug 16, 2026 FLT3 mutated AML Diagnosis, frontline therapy, MRD, and relapse  
Aug 13, 2026 ECOG-ACRIN CH Assay Comparison Standardized CH detection August 2026 Update  
Aug 12, 2026 Clonal Hematopoiesis From an incidental sequencing finding to a disease of aging blood  
Aug 11, 2026 Core Lecture: Management of APL Acute Promyelocytic Leukemia — diagnosis, risk stratification, and treatment  
Jul 2, 2026 ABNL-MARRO 001 — Arm A ASH 2026 Analysis Plan · ASTX727 + Itacitinib in MDS/MPN Overlap Syndromes  
Jun 1, 2026 EHA 2026: Top 10 in AML & MPN A Blood Cancer Talks reading guide — what the data say, and how sure we should be  
No matching items

NoteHow the listing is populated

Each field comes from the deck’s own YAML header:

---
title: "Myelofibrosis: beyond JAK inhibition"
subtitle: "Novel agents and combination strategies"
description: "Fellows' conference, 45 min. Covers pelabresib, navitoclax, selinexor."
categories: [MPN, Myelofibrosis, Therapeutics]
date: last-modified
---

categories drives the tag cloud and the topic menu in the navbar. Use a small, consistent vocabulary — five or six tags reused across decks beats forty used once.

To hide a work-in-progress deck from the listing without deleting it, add draft: true to its YAML.

© 2026 Ashwin Kishtagari. Content licensed CC BY 4.0.

Division of Hematology/Oncology · Vanderbilt University Medical Center

Built with Quarto